Trials / Completed
CompletedNCT02713256
A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CFZ533 | CFZ533 intravenously over approximately one hour |
Timeline
- Start date
- 2016-04-19
- Primary completion
- 2017-04-24
- Completion
- 2017-04-24
- First posted
- 2016-03-18
- Last updated
- 2021-01-05
- Results posted
- 2018-05-21
Locations
3 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02713256. Inclusion in this directory is not an endorsement.